• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球艾滋病控制:是悲观还是乐观?

Global HIV control: is the glass half empty or half full?

机构信息

Department of Epidemiology, Department of Infectious Diseases, Department of Microbiology, and Center for Global Health, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA; Department of Epidemiology and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University of Baltimore, MD, USA; Department of Medicine, Division of Infectious Diseases, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa.

Makerere University-Johns Hopkins University (MUJHU) Research Collaboration, Kampala, Uganda.

出版信息

Lancet HIV. 2023 Sep;10(9):e617-e622. doi: 10.1016/S2352-3018(23)00150-9. Epub 2023 Jul 25.

DOI:10.1016/S2352-3018(23)00150-9
PMID:37506723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10733629/
Abstract

The massive scale-up of HIV treatment and prevention over the past two decades has resulted in important reductions in new infections and mortality globally. Reduction in HIV incidence, however, has been unequal, with worsening epidemics in regions where the reach and scale of HIV control programmes have been insufficient, especially in eastern Europe, central Asia, the Middle East, north Africa, and Latin America where HIV epidemics are concentrated among key populations, including people who inject drugs, men who have sex with men, transgender people, and some minority racial and ethnic groups. The global state of the HIV pandemic highlights disparities in HIV control efforts and provides a roadmap for what should be done, including investment to better implement the effective HIV prevention and treatment tools that are available, but whose adoption and scale-up are not yet sufficient to get us close to an AIDS-free generation. To achieve the full potential of global HIV control, we call for urgent, evidence-informed implementation at scale of our existing and novel HIV prevention and treatment strategies in ways that are better, faster, more efficient, and cost-effective, especially in key populations and regions where the HIV pandemic continues to expand.

摘要

在过去的二十年中,艾滋病毒治疗和预防工作的大规模扩展,在全球范围内导致新感染和死亡率的显著下降。然而,艾滋病毒发病率的下降并不均衡,在艾滋病毒控制规划的覆盖面和规模不足的地区,疫情恶化,特别是在艾滋病毒流行集中于关键人群(包括注射毒品者、男男性行为者、跨性别者以及一些少数种族和族裔群体)的东欧、中亚、中东、北非和拉丁美洲。艾滋病毒大流行的全球现状突显了艾滋病毒防控工作中的差距,并为应该采取的措施提供了路线图,包括投资以更好地实施现有的和新的艾滋病毒预防和治疗工具,这些工具已经被证明是有效的,但它们的采用和推广还不足以使我们接近无艾滋病世代。为了充分发挥全球艾滋病毒防控的潜力,我们呼吁紧急、循证地在现有和新的艾滋病毒预防和治疗策略方面扩大规模,采取更好、更快、更高效和更具成本效益的方式,特别是在艾滋病毒继续蔓延的关键人群和地区。

相似文献

1
Global HIV control: is the glass half empty or half full?全球艾滋病控制:是悲观还是乐观?
Lancet HIV. 2023 Sep;10(9):e617-e622. doi: 10.1016/S2352-3018(23)00150-9. Epub 2023 Jul 25.
2
Status of the HIV epidemic in key populations in the Middle East and north Africa: knowns and unknowns.中东和北非关键人群中的艾滋病毒流行状况:已知和未知。
Lancet HIV. 2022 Jul;9(7):e506-e516. doi: 10.1016/S2352-3018(22)00093-5.
3
HIV and AIDS: where is the epidemic going?艾滋病毒与艾滋病:疫情将走向何方?
Bull World Health Organ. 1996;74(2):121-9.
4
Adequate funding of comprehensive community-based programs for key populations needed now more than ever to reach and sustain HIV targets.现在比以往任何时候都更需要为重点人群提供全面的基于社区的综合项目提供充足资金,以实现和维持艾滋病毒目标。
J Int AIDS Soc. 2022 Jul;25(7):e25967. doi: 10.1002/jia2.25967.
5
Tuberculosis结核病
6
Overview of the epidemiological conditions of HIV among key populations in Africa.非洲重点人群中艾滋病毒流行状况概述。
J Int AIDS Soc. 2021 Jul;24 Suppl 3(Suppl 3):e25716. doi: 10.1002/jia2.25716.
7
Engagement of Gay Men and Other Men Who Have Sex with Men (MSM) in the Response to HIV: A Critical Step in Achieving an AIDS-Free Generation.男同性恋者及其他男男性行为者参与应对艾滋病:迈向无艾滋病一代的关键一步。
AIDS Behav. 2016 Dec;20(Suppl 3):330-340. doi: 10.1007/s10461-016-1388-8.
8
Global estimates of HIV infections and AIDS cases: 1991.1991年全球艾滋病毒感染和艾滋病病例估计数。
AIDS. 1991;5 Suppl 2:S57-61. doi: 10.1097/00002030-199101001-00009.
9
Mobile Health App for Self-Learning on HIV Prevention Knowledge and Services Among a Young Indonesian Key Population: Cohort Study.移动健康应用程序在印度尼西亚青年关键人群中自我学习艾滋病预防知识和服务:队列研究。
JMIR Mhealth Uhealth. 2020 Sep 8;8(9):e17646. doi: 10.2196/17646.
10
The persistent and evolving HIV epidemic in American men who have sex with men.美国男男性行为者中持续演变的艾滋病病毒流行情况。
Lancet. 2021 Mar 20;397(10279):1116-1126. doi: 10.1016/S0140-6736(21)00321-4. Epub 2021 Feb 19.

引用本文的文献

1
Development and evaluation of an online HIV pre-exposure prophylaxis (PrEP) training program for community pharmacists to implement pharmacy-led PrEP services in Malaysia.为马来西亚社区药剂师开发并评估一项在线艾滋病毒暴露前预防(PrEP)培训计划,以实施由药房主导的PrEP服务。
PLoS One. 2025 Aug 18;20(8):e0328713. doi: 10.1371/journal.pone.0328713. eCollection 2025.
2
A Dyad-Based Intervention to Improve Adherence to Antiretroviral Therapy among People with HIV who Inject Drugs in Kazakhstan: Results of a Randomized Controlled Trial.哈萨克斯坦针对注射毒品的艾滋病毒感染者开展的基于二元组的抗逆转录病毒疗法依从性改善干预措施:一项随机对照试验的结果
AIDS Behav. 2025 Aug 7. doi: 10.1007/s10461-025-04841-5.
3

本文引用的文献

1
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.扩展多变量模型以辅助长效卡替拉韦+利匹韦林治疗的患者选择:与病毒学失败相关的患者、药物浓度和病毒因素组合的临床效用。
Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370.
2
Long-acting antiretrovirals and HIV treatment adherence.长效抗逆转录病毒药物和艾滋病治疗依从性。
Lancet HIV. 2023 May;10(5):e332-e342. doi: 10.1016/S2352-3018(23)00051-6. Epub 2023 Apr 14.
3
Cabotegravir-Global Access to Long-Acting Pre-exposure Prophylaxis for HIV.
Development of a Diagnostic Score for Histoplasmosis in a Cohort of Patients With HIV.
HIV感染患者队列中组织胞浆菌病诊断评分系统的开发
Open Forum Infect Dis. 2025 Jun 19;12(7):ofaf355. doi: 10.1093/ofid/ofaf355. eCollection 2025 Jul.
4
The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa.进步的代价:评估东非地区艾滋病毒/艾滋病管理的财务成本。
Medicine (Baltimore). 2025 May 2;104(18):e42300. doi: 10.1097/MD.0000000000042300.
5
Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic.吉尔吉斯共和国阿片类激动剂治疗项目的轨迹与进展
Glob Health Econ Sustain. 2024;2(4). doi: 10.36922/ghes.2536. Epub 2024 Sep 26.
6
Using nominal group technique to identify and prioritize barriers to decentralizing HIV care to primary health centers in Lima, Peru.运用名词组技术来识别秘鲁利马将艾滋病护理工作下放至初级卫生中心的障碍并确定其优先级。
BMC Health Serv Res. 2025 Mar 29;25(1):466. doi: 10.1186/s12913-025-12618-8.
7
Exploration of the multi-level barriers to scaling up methadone for HIV prevention among people who inject drugs in Kazakhstan.哈萨克斯坦扩大美沙酮用于预防注射吸毒者感染艾滋病毒的多层次障碍探索。
J Subst Use Addict Treat. 2025 May;172:209640. doi: 10.1016/j.josat.2025.209640. Epub 2025 Feb 20.
8
Disruptions to HIV Prevention During Armed Conflict in Ukraine and Other Settings.乌克兰及其他地区武装冲突期间艾滋病预防工作受到的干扰。
Curr HIV/AIDS Rep. 2024 Dec 14;22(1):10. doi: 10.1007/s11904-024-00716-x.
9
State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics.抗逆转录病毒疗法(ART)的现状:长效HIV-1治疗药物
Glob Health Med. 2024 Oct 31;6(5):285-294. doi: 10.35772/ghm.2024.01049.
10
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.针对轻度转氨酶升高的慢性乙型肝炎的抗病毒治疗:TORCH-B试验的一项延续性研究。
Clin Mol Hepatol. 2025 Jan;31(1):213-226. doi: 10.3350/cmh.2024.0640. Epub 2024 Oct 17.
卡博特韦——全球获得长效HIV暴露前预防药物
Open Forum Infect Dis. 2022 Dec 15;10(1):ofac673. doi: 10.1093/ofid/ofac673. eCollection 2023 Jan.
4
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.卡博特韦用于女性艾滋病毒 1 型的预防:来自 HPTN 084 的结果,一项 3 期、随机临床试验。
Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1.
5
Extending a lifeline to people with HIV and opioid use disorder during the war in Ukraine.在乌克兰战争期间向感染艾滋病毒和患有阿片类药物使用障碍的人伸出援助之手。
Lancet Public Health. 2022 May;7(5):e482-e484. doi: 10.1016/S2468-2667(22)00083-4. Epub 2022 Mar 28.
6
The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis.全球跨性别者中的 HIV 负担:一项更新的系统评价和荟萃分析。
PLoS One. 2021 Dec 1;16(12):e0260063. doi: 10.1371/journal.pone.0260063. eCollection 2021.
7
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.在感染 HIV-1 的成人中直接注射或口服先导药物启动长效卡替拉韦/利匹韦林:FLAIR 研究开放标签 3 期第 124 周结果。
Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14.
8
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.卡博特韦用于预防顺性别男性和跨性别女性中的 HIV。
N Engl J Med. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016.
9
HIV vaccinology: 2021 update.HIV 疫苗学:2021 年更新。
Semin Immunol. 2021 Jan;51:101470. doi: 10.1016/j.smim.2021.101470. Epub 2021 Jul 14.
10
The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?长效抗逆转录病毒疗法提高依从性的前景:有哪些数据?
J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:23259582211009011. doi: 10.1177/23259582211009011.